Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Journal	Journal of Clinical Oncology
Volume	40
Issue number	6
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{5fc7675d95c742f6bac274689c5936b4,

title = "Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer",

author = "Egils Vjaters and Karim Fizazi and \{Nicholas D.\}, James and James and Tammel Teuvo and \{Nicholas D.\} and Tammel and Teuvo",

year = "2022",

language = "English",

volume = "40",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer

AU - Vjaters, Egils

AU - Fizazi, Karim

AU - Nicholas D., James

AU - James, null

AU - Teuvo, Tammel

AU - Nicholas D., null

AU - Tammel, null

AU - Teuvo, null

PY - 2022

Y1 - 2022

UR - https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.090

M3 - Meeting abstract

SN - 0732-183X

VL - 40

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

ER -